NO792321L - Fremgangsmaate ved fremstilling av n-ethyl-gamma-pyridon-3-carboxylsyrederivater - Google Patents
Fremgangsmaate ved fremstilling av n-ethyl-gamma-pyridon-3-carboxylsyrederivaterInfo
- Publication number
- NO792321L NO792321L NO792321A NO792321A NO792321L NO 792321 L NO792321 L NO 792321L NO 792321 A NO792321 A NO 792321A NO 792321 A NO792321 A NO 792321A NO 792321 L NO792321 L NO 792321L
- Authority
- NO
- Norway
- Prior art keywords
- trimethoprim
- acid
- urinary tract
- day
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 3
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229960001082 trimethoprim Drugs 0.000 claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 28
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 12
- 229960000210 nalidixic acid Drugs 0.000 claims description 12
- 229960000321 oxolinic acid Drugs 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 8
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 claims description 8
- 229960004444 piromidic acid Drugs 0.000 claims description 8
- 208000019206 urinary tract infection Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 210000001635 urinary tract Anatomy 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- NFTOEHBFQROATQ-UHFFFAOYSA-N 2,3-dihydrofuran-5-carboxylic acid Chemical compound OC(=O)C1=CCCO1 NFTOEHBFQROATQ-UHFFFAOYSA-N 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
- 229960001225 rifampicin Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940047766 co-trimoxazole Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000001701 trimethoxybenzyl group Chemical group 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT50274/78A IT1156860B (it) | 1978-07-13 | 1978-07-13 | Applicazione terapeutica di trimethoprim e derivati dell'acido n-etil-piridone-3 carbossilico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO792321L true NO792321L (no) | 1980-01-15 |
Family
ID=11272626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO792321A NO792321L (no) | 1978-07-13 | 1979-07-12 | Fremgangsmaate ved fremstilling av n-ethyl-gamma-pyridon-3-carboxylsyrederivater |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4291035A (fr) |
| JP (1) | JPS5522671A (fr) |
| BE (1) | BE877703A (fr) |
| CA (1) | CA1136047A (fr) |
| CH (1) | CH639848A5 (fr) |
| DE (1) | DE2928426A1 (fr) |
| DK (1) | DK295079A (fr) |
| FR (1) | FR2430770A1 (fr) |
| GB (1) | GB2025224B (fr) |
| IE (1) | IE48376B1 (fr) |
| IL (1) | IL57760A (fr) |
| IT (1) | IT1156860B (fr) |
| LU (1) | LU81501A1 (fr) |
| NL (1) | NL7905510A (fr) |
| NO (1) | NO792321L (fr) |
| SE (1) | SE7906080L (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55129227A (en) * | 1979-03-28 | 1980-10-06 | Daito Koeki Kk | Antibacterial composition |
| JPS58118382A (ja) * | 1981-12-29 | 1983-07-14 | Yamatake Honeywell Co Ltd | ケ−ジ弁 |
| US20070166409A1 (en) * | 2006-01-17 | 2007-07-19 | Royds Robert B | Therapeutic compositions containing trimethoprim and cranberry extract and methods for treating and preventing urinary tract infections |
| US20170049779A1 (en) * | 2013-02-27 | 2017-02-23 | Okinawa Institute Of Science And Technology School Corporation | Flagellar and needle complex (injectosome) loop as anti bacterial drug target |
-
1978
- 1978-07-13 IT IT50274/78A patent/IT1156860B/it active
-
1979
- 1979-07-09 IL IL57760A patent/IL57760A/xx unknown
- 1979-07-11 US US06/056,657 patent/US4291035A/en not_active Expired - Lifetime
- 1979-07-12 NO NO792321A patent/NO792321L/no unknown
- 1979-07-12 DK DK295079A patent/DK295079A/da not_active Application Discontinuation
- 1979-07-12 SE SE7906080A patent/SE7906080L/xx not_active Application Discontinuation
- 1979-07-12 CA CA000331653A patent/CA1136047A/fr not_active Expired
- 1979-07-12 GB GB7924414A patent/GB2025224B/en not_active Expired
- 1979-07-12 CH CH651879A patent/CH639848A5/it not_active IP Right Cessation
- 1979-07-13 JP JP8976179A patent/JPS5522671A/ja active Pending
- 1979-07-13 BE BE0/196303A patent/BE877703A/fr not_active IP Right Cessation
- 1979-07-13 FR FR7918238A patent/FR2430770A1/fr active Granted
- 1979-07-13 DE DE19792928426 patent/DE2928426A1/de not_active Withdrawn
- 1979-07-13 NL NL7905510A patent/NL7905510A/nl not_active Application Discontinuation
- 1979-07-13 LU LU81501A patent/LU81501A1/fr unknown
- 1979-08-08 IE IE1349/79A patent/IE48376B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL7905510A (nl) | 1980-01-15 |
| GB2025224A (en) | 1980-01-23 |
| IE48376B1 (en) | 1984-12-26 |
| GB2025224B (en) | 1983-02-09 |
| US4291035A (en) | 1981-09-22 |
| IT7850274A0 (it) | 1978-07-13 |
| DK295079A (da) | 1980-01-14 |
| CA1136047A (fr) | 1982-11-23 |
| IT1156860B (it) | 1987-02-04 |
| SE7906080L (sv) | 1980-01-14 |
| BE877703A (fr) | 1979-11-05 |
| IL57760A (en) | 1983-03-31 |
| IE791349L (en) | 1980-02-13 |
| FR2430770B1 (fr) | 1982-11-19 |
| DE2928426A1 (de) | 1980-01-31 |
| JPS5522671A (en) | 1980-02-18 |
| LU81501A1 (fr) | 1979-10-31 |
| CH639848A5 (it) | 1983-12-15 |
| FR2430770A1 (fr) | 1980-02-08 |
| IL57760A0 (en) | 1979-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021068614A1 (fr) | Application d'honokiol et de magnolol dans la préparation d'un inhibiteur d'enzyme mcr-1 | |
| US20210275476A1 (en) | Bactericidal and virucidal pharmaceutical composition | |
| US4835140A (en) | Method for treating pneumocystis carinii pneumonia patients with clindamycin and primaquine | |
| CA2440744C (fr) | Agent de regulation d'expression d'il-12 | |
| JP2010510973A (ja) | 心筋組織の壊死を処置するためのホスホエノールピルビン酸誘導体の使用 | |
| Humble et al. | Staphylococcal bacteraemia, fusidic acid, and jaundice. | |
| Dance et al. | Interactions in vitro between agents used to treat melioidosis | |
| CN114099492B (zh) | 天然药物在制备抗菌药物中的应用 | |
| US5354771A (en) | Methods for treatment of sepsis using branch chain amino acids | |
| CN111939156B (zh) | 一种联合抗菌药物组合物及其应用 | |
| Figueredo et al. | Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis | |
| NO792321L (no) | Fremgangsmaate ved fremstilling av n-ethyl-gamma-pyridon-3-carboxylsyrederivater | |
| WO2021198940A1 (fr) | Composition destinée à prévenir ou soigner une infection virale chronique ou aiguë et/ou une septicémie chez l'être humain ou chez l'animal | |
| Pancoast et al. | Clinical evaluation of piperacillin therapy for infection | |
| CN110215445B (zh) | 香草酸在抑制多重耐药霍氏肠杆菌生长中的应用 | |
| EP0621783A1 (fr) | Formulations pharmaceutiques comprenant un sel d'acide clavulanique et un derive d'erythromycine | |
| Segev et al. | Pefloxacin treatment of meningitis caused by gram-negative bacteria | |
| EA029149B1 (ru) | Фармацевтические композиции, содержащие цефтаролина фозамил, для лечения бактериальных инфекций | |
| JP5775096B2 (ja) | インフルエンザの治療剤または予防剤 | |
| Yoshikawa et al. | Endocarditis due to Pseudomonas aeruginosa in a heroin addict: Successful treatment with trimethoprim-sulfamethoxazole mixture plus colistin | |
| KR20210036661A (ko) | Mmagnu2 화합물을 유효성분으로 함유하는 결핵균, 비결핵 항산균 또는 그람 양성균 감염 질환 예방 또는 치료용 조성물 | |
| RU2614730C1 (ru) | Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза | |
| US12016874B2 (en) | Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections | |
| CN112168812A (zh) | 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途 | |
| JP4589126B2 (ja) | 抗感染剤の生物学的有効性に影響を及ぼすためのクミン（ｃｕｍｉｎｕｍｃｙｍｉｎｕｍ）抽出物及びピペリンの使用 |